Impakter
  • EXPERT INSIGHT
  • PARTNERS
  • ABOUT US
    • Our Story
    • Team
    • Write for Impakter
    • Contact Us
    • Privacy Policy
No Result
View All Result
  • Climate
  • Business
  • Energy
  • Tech
  • Politics
  • Health
  • Food & Agriculture
  • Society
  • Climate
  • Business
  • Energy
  • Tech
  • Politics
  • Health
  • Food & Agriculture
  • Society
No Result
View All Result
Impakter
No Result
View All Result

Musk’s Neuralink to Start Testing Brain Implants in Humans

Brain implant startup granted the go-ahead for pioneering study to assist paralysis patients

byHannah Fischer-Lauder
September 20, 2023
in Science
brain implants neuralink elon musk

An independent review board has given Neuralink, billionaire entrepreneur Elon Musk’s brain implant startup, approval to recruit paralysis patients for its inaugural human trial.

The groundbreaking study aims to test an experimental brain-computer interface (BCI) device designed to assist individuals suffering from paralysis, particularly those with cervical spinal cord injuries or amyotrophic lateral sclerosis (ALS).

As Neuralink explains, the BCI implants will be surgically placed in participants’ brains, using robots, in the regions controlling movement. The objective: Allow participants to control computer cursors or keyboards using their thoughts alone.

The trial, spanning approximately six years, represents a critical milestone in Neuralink’s pursuit of revolutionizing brain technology. When and where the trials will take place remains unknown, as does the number of participants.

This development follows Neuralink’s previous efforts to obtain regulatory clearance for human trials. Last year, the Food and Drug Administration (FDA) initially denied the request for expedited trials, but subsequently granted an investigational device exemption (IDE) in May, allowing the brain device to be used in clinical studies.


Related Articles: Neuralink Receives FDA Approval for Testing Brain Implants in Humans | Brain Implants in the Human Brain: Too Soon? Too Dangerous?

Elon Musk’s company, however, still faces ongoing scrutiny regarding its previous tests on animals. Former Neuralink employees have raised concerns about the handling of animal trials, saying they caused unnecessary suffering.

This has prompted investigations by multiple regulatory bodies, including the Department of Agriculture and the Department of Transportation, probing alleged animal abuse and biohazardous material mishandling.

If the implant trial demonstrates the safety and efficacy of the BCI device, Musk says it could potentially pave the way for extensive applications in treating various medical conditions, including obesity, autism, depression, and schizophrenia.

However, experts caution that even with positive human study outcomes, securing commercial use clearance may take more than a decade.


Editor’s Note: The opinions expressed here by the authors are their own, not those of Impakter.com — Featured Photo Credit: Steve Jurvetson.

Share
WhatsApp LinkedIn X Facebook
Tags: BCIBrain-Computer InterfaceBrain-implantsElon MuskFDAHuman trialsmicrochipsMuskNeuralink
Previous Post

Victoria’s Secret’s Comeback: Embracing Diversity and Inclusivity

Next Post

Work From Home Can Cut Worker Emissions by 54%, Study Shows

Hannah Fischer-Lauder

Hannah Fischer-Lauder

Hannah Fischer-Lauder is an anthropologist and a graduate of McGill University. After 15 years of field research in Madagascar and New Guinea, she has returned to Europe and America to study cultural diversity in western society.

Next Post
remote work

Work From Home Can Cut Worker Emissions by 54%, Study Shows

Related News

Historic image from 1966 depicting a Robert K. Price public health exhibit that focused on the eradication of measles.

Beyond the Measles Resurgence: Strengthening Health Security Through One Health

November 18, 2026

COP31 Will Be a Failure if Developed Countries Don’t Deliver on Adaptation, Says WWF

November 18, 2026

Impakter keeps you informed through its ESG news platform and empowers your business through the Impakter Index.

To assess and improve your company’s ESG performance, explore Klimado’s ESG dashboard and assessment tools at www.klimado.com.

Registered Office Address

Klimado GmbH
Niddastrasse 63,

60329, Frankfurt am Main, Germany


IMPAKTER is a Klimado GmbH website

Impakter is a publication that is identified by the following International Standard Serial Number (ISSN) is the following 2515-9569 (Printed) and 2515-9577 (online – Website).


Office Hours - Monday to Friday

9.30am - 5.00pm CEST


Email

stories [at] impakter.com

By Audience

  • TECH
    • Start-up
    • AI & Machine Learning
    • Green Tech
  • ENVIRONMENT
    • Biodiversity
    • Energy
    • Circular Economy
    • Climate Change
  • INDUSTRY NEWS
    • Entertainment
    • Food and Agriculture
    • Health
    • Politics & Foreign Affairs
    • Philanthropy
    • Science
    • Sport
    • Editorial Series

ESG/Finance Daily

  • ESG News
  • Business

About Us

  • Team
  • Partners
  • Write for Impakter
  • Contact Us
  • Privacy Policy

© 2026 IMPAKTER. All rights reserved.

No Result
View All Result
  • Climate
  • Business
  • Energy
  • Tech
  • Politics
  • Health
  • Food & Agriculture
  • Society

© 2026 IMPAKTER. All rights reserved.